-
公开(公告)号：EP3183268B1
公开(公告)日：2020-02-12
申请号：EP15756525.0
申请日：2015-08-19
发明人： KENDERIAN, Saad , BROGDON, Jennifer , GILL, Saar , GLASS, David , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , PORTER, David L. , RUELLA, Marco , WANG, Yongqiang , WU, Qilong , ZHANG, Jiquan
IPC分类号： C07K16/28 , A61K39/395
-
12.发明公开TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR 审中-公开TOR UNG ON ON BS TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR
公开(公告)号：EP3129470A1
公开(公告)日：2017-02-15
申请号：EP15719043.0
申请日：2015-04-07
发明人： BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl, H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David, L. , RUELLA, Marco , SELLERS, William, Raj , WASIK, Mariusz , BROGDON, Jennifer
IPC分类号： C12N5/0783 , A61K35/17 , A61K31/00 , A61P35/02
CPC分类号： A61K35/17 , A61K31/436 , A61K31/519 , A61K31/53 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , C07K14/7051 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/03 , C12N5/0636 , C12N2501/599 , C12N2501/727 , C12N2510/00 , A61K2300/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
摘要翻译： 本发明提供了用于治疗与CD19表达相关的疾病的组合物和方法，例如通过如本文所述施用包含本文所述的CD19 CAR的重组T细胞与激酶抑制剂，例如本文所述的激酶抑制剂组合。 本发明还提供了本文所述的试剂盒和组合物。
-
公开(公告)号：EP3087101A1
公开(公告)日：2016-11-02
申请号：EP14872734.0
申请日：2014-12-19
申请人： Novartis AG , The Trustees of The University of Pennsylvania , Brogdon, Jennifer , Engels, Boris , GLASS, David, Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , Milone, Michael C. , MURPHY, Leon , SELLERS, William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
发明人： BROGDON, Jennifer , ENGELS, Boris , GLASS, David Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , SELLERS,William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
IPC分类号： C07K19/00 , C12N5/0783
CPC分类号： C07K16/2863 , A61K31/436 , A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K14/71 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/41 , C07K2319/43 , C07K2319/70 , C12N9/1205 , C12N9/90 , C12Y502/00
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
摘要翻译： 提供了与可调节嵌合抗原受体（RCAR）相关的组合物和方法，其中可以控制RCAR的细胞内信号传导或增殖以优化使用表达RCAR的细胞以提供免疫应答。 例如，RCAR可以包含二聚转换开关，其在存在二聚化分子时可以将细胞内信号转导域偶联到细胞外识别元件，例如抗原结合结构域，抑制性反配体结合结构域或共刺激ECD结构域 。 RCAR可以被设计成包括对所需抗原靶特异性并用于治疗疾病的合适的抗原结合结构域。
-
公开(公告)号：EP4406610A2
公开(公告)日：2024-07-31
申请号：EP24166976.1
申请日：2015-04-07
发明人： BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David L. , RUELLA, Marco , SELLERS, William Raj , WASIK, Mariusz , BROGDON, Jennifer
IPC分类号： A61P35/02
CPC分类号： C12N5/0636 , C12N2501/72720130101 , C07K16/2803 , A61K31/519 , A61K45/06 , A61K31/436 , A61K31/53 , C07K2317/62220130101 , C07K2319/0320130101 , C07K2317/7320130101 , A61P35/00 , A61P35/02 , A61P43/00 , A61K39/001112 , A61K2239/3820230501 , A61K39/4631 , A61K2239/2620230501 , A61K2239/4820230501 , A61K39/464412 , A61K2239/3120230501 , A61K39/4611 , A61K39/4636
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
-
公开(公告)号：EP3888674A1
公开(公告)日：2021-10-06
申请号：EP21160203.2
申请日：2015-04-07
发明人： BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David L. , RUELLA, Marco , SELLERS, William Raj , WASIK, Mariusz , BROGDON, Jennifer
IPC分类号： A61K39/00 , A61K35/17 , A61K31/436 , A61P35/02
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
-
16.发明公开BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO CHIMERIC ANTIGEN RECEPTOR THERAPY AND USES THEREOF 审中-公开生物标志物对治疗对嵌合抗原受体治疗反应的预测及其应用
公开(公告)号：EP3204777A1
公开(公告)日：2017-08-16
申请号：EP15791387.2
申请日：2015-10-07
发明人： DORFMEIER, Corin , WILCOX, Nicholas , BEDOYA, Felipe , BITTER, Hans , BROGDON, Jennifer , GARG, Abhishek , GLASS, David , MANNICK, Joan , MELENHORST, Jan J. , MILONE, Michael C. , MURPHY, Leon , ORLANDO, Elena
IPC分类号： G01N33/574 , C12N5/0783
CPC分类号： C12Q1/6886 , A61K39/0011 , A61K2039/5158 , C12N5/0636 , C12Q2600/118 , C12Q2600/158 , G01N33/574 , G01N33/57426 , G01N2800/52
摘要： Cancer biomarkers and methods of using them are disclosed.
摘要翻译： 公开了癌症生物标志物和使用它们的方法。
-
公开(公告)号：EP3297629A1
公开(公告)日：2018-03-28
申请号：EP16725601.5
申请日：2016-05-20
申请人： Novartis AG
发明人： GLASS, David , MANNICK, Joan , MURPHY, Leon
IPC分类号： A61K31/436 , A61K31/4745 , A61P37/04 , A61P35/00 , A61P25/00
CPC分类号： A61K31/4745 , A61K31/436 , A61K2300/00
摘要： The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.
-
公开(公告)号：EP3068435A1
公开(公告)日：2016-09-21
申请号：EP14815965.0
申请日：2014-11-13
申请人： Novartis AG
IPC分类号： A61K45/06 , A61K31/436 , A61P35/00 , A61P37/04 , A61K39/00 , A61K39/09 , A61K39/145 , A61K31/4745 , A61K31/519 , A61K39/12
CPC分类号： A61K39/39 , A61K31/436 , A61K31/4745 , A61K31/519 , A61K39/00 , A61K39/09 , A61K39/092 , A61K39/12 , A61K39/145 , A61K45/06 , A61K2039/55511 , C12N7/00 , C12N2760/16034 , G01N33/6854
摘要： The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
-
19.发明授权COMBINATIONS OF THERAPEUTIC AGENTS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES 有权治疗剂中的用途，神经变性疾病处理后的组合
公开(公告)号：EP2675450B1
公开(公告)日：2016-02-10
申请号：EP12705457.5
申请日：2012-02-14
申请人： Novartis AG
发明人： GALIMBERTI, Ivan , MURPHY, Leon
IPC分类号： A61K31/436 , A61K31/4745 , A61K31/5377 , A61K31/52 , A61K31/496 , A61K45/06 , A61P25/00
CPC分类号： A61K31/5377 , A61K31/436 , A61K31/4745 , A61K31/496 , A61K31/52 , A61K45/06 , A61K2300/00
-
公开(公告)号：EP2129379B1
公开(公告)日：2019-04-10
申请号：EP08730106.5
申请日：2008-02-19
申请人： Novartis AG
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.042 秒)
